UNSPSC 51343802: Abacavir/lamivudine/zidovudine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

The first component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but more generally known as abacavir, which bears U.S. National Institutes of Health Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine.

UNSPSC 51343802 Abacavir/lamivudine/zidovudine is a Commodity code that nominally names a single antiretroviral pharmaceutical product, but the recent state and local opportunities tagged under it show little activity aligned with that specific drug. Instead, the posted opportunities involve other pharmaceuticals—antibiotics, naloxone, and drug deactivation systems—procured through warehouse and direct-purchase channels by state health departments and county governments. State and local agencies acquire pharmaceuticals under this code through piggyback arrangements with established pharmaceutical consortiums and through competitive bidding for specific drugs to support public health missions, including emergency response and community health initiatives.

Recent activity spans Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Solicitation 26482DPHPREPDB53392, Invitation for Bid, $2,999,999.11 over three years) for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets with quarterly deliveries and renewal options. Seminole County, Florida released an Invitation for Bid on June 30, 2026 (Solicitation IFB60459723LAS, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and potential FEMA funding. The mismatch between the code's nominal scope and the actual pharmaceuticals being solicited suggests either broad tagging practices within state procurement systems or limited recent demand specifically for the coded product.